236 related articles for article (PubMed ID: 27178681)
41. Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer.
Green MR; West H; Socinski MA; Willey J; Daniels L; Lemke K; Rafferty G; Iovino L
J Thorac Oncol; 2009 Aug; 4(8):983-7. PubMed ID: 19561551
[TBL] [Abstract][Full Text] [Related]
42. American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges.
Somerfield MR; Einhaus K; Hagerty KL; Brouwers MC; Seidenfeld J; Lyman GH;
J Clin Oncol; 2008 Aug; 26(24):4022-6. PubMed ID: 18711193
[TBL] [Abstract][Full Text] [Related]
43. Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer.
Morgensztern D; Pennell NA; Subramanian J; Govindan R
Clin Lung Cancer; 2011 Mar; 12(2):94-9. PubMed ID: 21550555
[TBL] [Abstract][Full Text] [Related]
44. Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice.
Tam VC; Tannock IF; Massey C; Rauw J; Krzyzanowska MK
J Clin Oncol; 2011 Aug; 29(23):3133-9. PubMed ID: 21747079
[TBL] [Abstract][Full Text] [Related]
45. Cancer gene therapy based on the abstracts of the 2003 ASCO meeting and recent publications.
Ahmed CM
Drugs Today (Barc); 2004 Aug; 40(8):723-31. PubMed ID: 15510243
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Sharma C; Horowitz D; Chabot J; Saif MW
JOP; 2011 Jul; 12(4):343-6. PubMed ID: 21737892
[TBL] [Abstract][Full Text] [Related]
47. Ethics in oncology: consulting for the investment industry.
Berlin J; Bruinooge SS; Tannock IF
J Clin Oncol; 2007 Feb; 25(4):444-6. PubMed ID: 17264341
[TBL] [Abstract][Full Text] [Related]
48. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.
J Clin Oncol; 1996 May; 14(5):1730-6; discussion 1737-40. PubMed ID: 8622094
[TBL] [Abstract][Full Text] [Related]
49. Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Dimou AT; Syrigos KN; Saif MW
JOP; 2010 Jul; 11(4):324-7. PubMed ID: 20601803
[TBL] [Abstract][Full Text] [Related]
50. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
51. The ASH/ASCO clinical guidelines on the use of erythropoietin.
Lichtin A
Best Pract Res Clin Haematol; 2005; 18(3):433-8. PubMed ID: 15792917
[TBL] [Abstract][Full Text] [Related]
52. The current look at high-dose chemotherapy in breast cancer minireview.
Filip S; Petera J; Odrázka K; Bláha M
Neoplasma; 2000; 47(5):261-8. PubMed ID: 11130240
[TBL] [Abstract][Full Text] [Related]
53. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
[TBL] [Abstract][Full Text] [Related]
54. Profiling clinical cancer research across the Atlantic: a review of research and its characteristics presented at ASCO and ESMO Congresses during the last decade.
Pentheroudakis G; Krikelis D; Cervantes A; Vermorken J; Pavlidis N
Cancer Treat Rev; 2012 Oct; 38(6):560-5. PubMed ID: 22209684
[TBL] [Abstract][Full Text] [Related]
55. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
56. First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Merl MY; Abdelghany O; Li J; Saif MW
JOP; 2010 Jul; 11(4):317-20. PubMed ID: 20601801
[TBL] [Abstract][Full Text] [Related]
57. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
58. [American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].
Vignot S; Bay JO; Blay JY; Gonçalves A; Massard C; Thariat J; Wislez M; André T
Bull Cancer; 2011 Dec; 98(12):1509-23. PubMed ID: 22182714
[TBL] [Abstract][Full Text] [Related]
59. [Report of the ASCO and AACR II congress, San Diego, 17-23 May 1992. Plenary session and urologic oncology sessions].
Droz JP
Bull Cancer; 1992; 79(9):909-15. PubMed ID: 1362506
[No Abstract] [Full Text] [Related]
60. World conference on lung cancer.
Felip E; Rosell R
Expert Opin Biol Ther; 2003 Dec; 3(8):1295-8. PubMed ID: 14640956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
